INOVIQ (ASX:IIQ): New Research Report Highlights Exosome Tech Leadership and Upgraded Valuation
Excited to share the latest MST Access research (Analyst Reports | INOVIQ) from analyst Chris Kallos on INOVIQ, a leader in exosome-powered diagnostics and therapeutics. The new report underscores INOVIQ’s position at the forefront of the rapidly growing exosome market, with breakthrough advances in cancer care.Key Highlights:
- Exosome Tech Leadership: Proven platform with on-market research tools and a high-value pipeline across diagnostics and therapeutics.
- Ovarian Cancer Screening Test: New ASCO 2025 data shows IIQ’s test achieved 77% all-stage and 100% stage I/II sensitivity at >99.6% specificity—potentially best-in-class for screening ovarian cancer in asymptomatic women.
- Triple Negative Breast Cancer Therapy: Proprietary CAR-exosome program demonstrates 88% tumour cell death in vitro—potentially first-in-class CAR-exosome therapy with cost, safety, and efficacy advantages over autologous CAR-T therapies.
Valuation Update:
Valuation increased to A$4.37/share (from A$3.42) on the back of strong progress in EXO-OC™ ovarian cancer test and the addition of the CAR-EV program for TNBC.
INOVIQ is advancing next-gen solutions to transform cancer care and improve patient outcomes. For more details, check out the full report or visit INOVIQ’s website.
I had sent this to the email bin before I saw its not on here
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.020(5.00%) |
Mkt cap ! $46.88M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.5¢ | 40.0¢ | $81.16K | 193.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16684 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 6950 | 1 |
View Market Depth
| Last trade - 14.27pm 08/08/2025 (20 minute delay) ? |
| IIQ (ASX) Chart |